Manager/Sr. Manager, IR & Corporate Communications

Are you ready to join a team committed to making a meaningful impact on cancer treatment through the discovery and development of precision medicines? At Kura Oncology, you have an opportunity to be a part of something bigger, with a lasting impact that you can be proud of.

At Kura Oncology, we are working to change the paradigm and improve the science of cancer treatment. As an organization, we strive to cultivate a diverse and talented professional culture driven to develop precision medicine therapeutics.

As we continue to build a leading biotech organization with a strong culture, a patient-focused mindset and a team focused on relentless execution, we are looking for innovative, passionate professionals to join us and make our vision a reality.

To succeed at Kura, you will need to have a demonstrated ability for excellence in drug discovery and development and a roll-up your sleeves attitude. The ideal candidate will possess a values-driven work style where integrity and grit drive all behaviors, decisions, and actions.

ESSENTIAL JOB FUNCTIONS:

• Partner with the SVP of IR and Corp Affairs as well as the Senior Director, Corporate Communications to develop and execute Kura’s communications strategies and tactics to amplify our story and advance our reputation
• Support product communications in collaboration with clinical and commercial teams
• Partners with Commercial to manage and execute the company’s social media strategies and enhance patient advocacy relationships
• Partners with Human Resources to assist with internal communications, drive employee engagement and further strengthen corporate culture
• Support internal communications by drafting articles for the Company intranet and supporting the periodic newsletter distribution
• Manage corporate social media content and calendar across LinkedIn, X (Twitter), YouTube, and other platforms; track performance analytics
• Coordinates and maintains a communications calendar
• Support preparation of investor relations materials, including press releases, conference call scripts and presentations
• Analyze industry/market trends and perform competitor analysis. Communicate relevant insights to the IR team and leadership
• Coordinate logistics for investor conferences and events.
• Manage updates to corporate website to ensure compliance with public disclosure, positioning, key corporate messages, and regulatory requirements
• Supports community relations and corporate giving efforts and other CSR activities on behalf of the company; creates materials and content to showcase our community efforts externally
• Coordinates and supports leadership team with media interviews, speaking engagements and participation in investor events
• Oversee the use of corporate brand standards and style guidelines to ensure quality and uniformity across all communications channels
• Ensures high quality and timely results for all communications
• Other duties as requested by supervisor

JOB SPECIFICATIONS:

• Accredited Bachelor’s degree preferably in Communications, English, Journalism or related field
• Prior experience in biopharmaceutical industry in a corporate or agency role strongly preferred
• Relevant experience in corporate communications or related field
• Ability to demonstrate strong presence and cultivate relationships with senior leadership team
• Outstanding interpersonal and communication skills, both written and verbal
• Interest/knowledge in graphic design and the interplay between user interfaces and experience, copywriting and content strategy
• Self-starter, able to work well as a member of a team, but also work independently with limited oversight
• Track record of managing issues and ability to stay calm under pressure
• Strong project management skills and a history of driving projects to completion in a fast-paced environment
• General working knowledge of essential computer applications (i.e. MS Word, Excel, PowerPoint, CRM)
• Ability to influence others
• Ability to multi-task

The base range for a Manager is $145,000 - $168,000 and a Senior Manager is $175,000 - $220,000 per year. Individual pay may vary based on additional factors, including, and without limitation, job-related skills, experience, work location, and relevant education or training. Kura's compensation package also includes generous benefits, equity, and participation in an annual target bonus.

#LI-RM1

Kura’s Values that are used for candidate selection and performance assessments:

• We work as one for patients
• We are goal-focused and deliver with excellence
• We are science-driven courageous innovators
• We strive to bring out the best in each other and ourselves

The Kura Package

• Career advancement/ development opportunities
• Competitive comp package
• Bonus
• 401K + Employer contributions
• Generous stock options
• ESPP Plan
• 20 days of PTO to start
• 18 Holidays  (Including Summer & Winter Break)
• Generous Benefits Package with a variety of plans available with a substantial employer match
• Paid Paternity/Maternity Leave
• In-Office Catered lunches
• Home Office Setup
• Lifestyle Spending Stipend
• Commuter Stipend (Boston Office)
• Regular employee social activities, including happy hours, monthly birthday celebrations, Kura Koffee Talks, and much more!

Kura Oncology is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer. The Company’s pipeline consists of small molecule drug candidates designed to target cancer signaling pathways. Ziftomenib, a once-daily, oral menin inhibitor, is the first and only investigational therapy to receive Breakthrough Therapy Designation from the U.S. Food and Drug Administration (“FDA”) for the treatment of relapsed/refractory (“R/R”) NPM1-mutant acute myeloid leukemia (“AML”). In November 2024, Kura Oncology entered into a global strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize ziftomenib for AML and other hematologic malignancies. Enrollment in a Phase 2 registration-directed trial of ziftomenib in R/R NPM1-mutant AML has been completed, and in the second quarter of 2025, the companies announced the FDA’s acceptance of a New Drug Application for ziftomenib for the treatment of adult patients with R/R NPM1-mutant AML and assignment of a Prescription Drug User Fee Act target action date of November 30, 2025. Kura Oncology and Kyowa Kirin are also conducting a series of clinical trials to evaluate ziftomenib in combination with current standards of care in newly diagnosed and R/R NPM1-mutant and KMT2A-rearranged AML. KO-2806, a next-generation farnesyl transferase inhibitor, is being evaluated in a Phase 1 dose-escalation trial as a monotherapy and in combination with targeted therapies for patients with various solid tumors. Tipifarnib, a potent and selective farnesyl transferase inhibitor, is currently in a Phase 1/2 trial in combination with alpelisib for patients with PIK3CA-dependent head and neck squamous cell carcinoma. For additional information, please visit Kura’s website at www.kuraoncology.com and follow us on X and LinkedIn.

Kura Oncology is committed to creating a diverse environment and is proud to be an equal opportunity employer. All qualified applicants will receive consideration for employment without regard to race, color, religion, gender, gender identity or expression, sexual orientation, national origin, genetics, disability, age, or veteran status. 

If you are a California resident, please see the attached Privacy Notice CA Privacy Notice